About Us
Implant Therapeutics Offers
Implant Therapeutics provides universally safe therapeutic MSC for:
- Bioproduction
- Feeder lines and manufacturing
- Ex-vivo gene therapy
- Autologous transplant therapy
- Allogeneic transplant therapy
- Autologous or Allogeneic cancer therapy
- Tolerization and vaccination
Why Implant Therapeutics
IPSC-MSC offer cells with the same characteristics as adult derived cells with two advantages:
- Ability to gene edit
- Ability to make true hypoimmunogeneic cells in a scalable way
The ability to make hypoimmunogenic cells make IPSC MSC the choice for bone, cartilage and tendon replacement strategies combining the advantages of allogeneic and autologous cells as well as allowing them to be used as ex-vivo gene therapy vehicles.
Implant Therapeutics combines the advantages of iPSC-MSC with panCELLa’s exclusive safety platforms to deliver the ultimate therapeutic MSC products.
Experience the Difference
Implant Therapeutic Services
- Cells/Cell lines for bioproduction uses including exosome manufacture
- iPSC derived MSC unmodified for therapy (eg: GVH, ARDS)
- iPSC derived MSC modified with a safe harbor site for over expression of antigen, missing factor or antibody delivery, etc.
- Cloaked or Hypoimmunogenic iPSC derived MSC differentiated into bone or cartilage for repair
- iPSC derived MSC for composite tissue and organoids
- HLA null MSC for a variety of additional uses – (eg feeder cells for NK and HSC manufacture)
- Cells for vaccine therapy including antigens and antibodies
